This trial is for endometrial cancer patients with different molecular profiles. They will be assigned to different trials based on their profile and will receive different adjuvant therapies.
4 Primary · 8 Secondary · Reporting Duration: 3 years, 5 years
Active Control
Experimental Treatment
1611 Total Participants · 7 Treatment Groups
Primary Treatment: Chemotherapy · No Placebo Group · Phase 2 & 3
Age 18+ · Female Participants · 1 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: